Dexcom Inc Insider Trading
Every director, officer and 10% holder of Dexcom Inc has to report each trade in its stock within two business days of making it. This is those filings.
DXCM on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Nicholas AugustinosDirector2026-09-156.5K shat $84.04 | Sale10b5-1 plan | $549.5K |
| Michael Jon BrownEVP Chief Legal Compliance Off2026-09-151.7K shat $84.04 | Sale10b5-1 plan | $142.9K |
| Nicholas AugustinosDirector2026-09-141.6K shat $84.02 | Sale10b5-1 plan | $130.2K |
| Jereme M SylvainEVP, Chief Financal Officer2026-09-103.6K shat $83.27 | Sale10b5-1 plan | $302.9K |
| Sadie SternEVP Chief People & Culture Off2026-08-272.6K shat $88.37 | Sale10b5-1 plan | $226.7K |
| Kevin R SayerExecutive Chair2026-08-2019.3K shat $89.71 | Sale10b5-1 plan | $1.7M |
| Kevin R SayerExecutive Chair2026-08-207.4K shat $90.78 | Sale10b5-1 plan | $667.3K |
| Kevin R SayerExecutive Chair2026-08-2097 shat $91.41 | Sale10b5-1 plan | $8.9K |
| Michael Jon BrownEVP Chief Legal Compliance Off2026-08-141.7K shat $91.93 | Sale10b5-1 plan | $156.3K |
| Bridgette P HellerDirector2026-08-121K shat $88.29 | Sale10b5-1 plan | $89.3K |
| Mark G FolettaDirector2026-08-032K shat $85.32 | Sale10b5-1 plan | $170.6K |
| Mark G FolettaDirector2026-07-312K shat $80.00 | Sale10b5-1 plan | $160K |
| Kevin R SayerExecutive Chair2026-07-2026.8K shat $76.32 | Sale10b5-1 plan | $2M |
| Michael Jon BrownEVP Chief Legal Compliance Off2026-07-151.7K shat $74.42 | Sale10b5-1 plan | $126.5K |
| Kevin R SayerExecutive Chair2026-07-0626.8K shat $72.00 | Sale10b5-1 plan | $1.9M |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on DXCM
Follow Dexcom Inc (DXCM) by email
New trades in Dexcom Inc (DXCM) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.